Clinical Perspectives in Brain Metastasis.

Antineoplastic Agents / therapeutic use Brain Neoplasms / secondary Combined Modality Therapy Cranial Irradiation / methods Humans Quality of Life Radiosurgery / methods

Journal

Cold Spring Harbor perspectives in medicine
ISSN: 2157-1422
Titre abrégé: Cold Spring Harb Perspect Med
Pays: United States
ID NLM: 101571139

Informations de publication

Date de publication:
01 06 2020
Historique:
pubmed: 17 10 2019
medline: 24 7 2021
entrez: 17 10 2019
Statut: epublish

Résumé

Brain metastases (BMs) are responsible for decline in neurological function, reduction in overall quality of life, and mortality from recurrent or untreatable lesions. Advances in diagnostics and imaging have led to increased detection of central nervous system (CNS) metastases in patients with progressive cancers. Improved control of extracranial systemic disease, and the limited ability of current therapeutics to cross the blood-brain barrier (BBB) also contribute to the increase in incidence of brain metastases, as tumor cells seek refuge in the brain. Surgery, chemotherapy, and/or radiation (whole-brain radiation therapy and stereotactic radiation surgery [WBRT/SRS]) are a clinically established treatment paradigm for patients with brain metastases. With the advent of genetic and molecular characterization of tumors and their immune microenvironment, clinical trials seek to include targeted drugs into the therapeutic regimen for eligible patients. Several challenges, like treatment of multiple CNS lesions, superior uptake of chemotherapy into the brain, and trials with multidisciplinary approaches, are now being clinically addressed.

Identifiants

DOI: 10.1101/cshperspect.a037051 PMID: 31615863 PMC: PMC7263089
pubmed: 31615863
pii: cshperspect.a037051
doi: 10.1101/cshperspect.a037051
pmc: PMC7263089
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Références

Lancet Oncol. 2018 Jul;19(7):880-888
pubmed: 29804905
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9
pubmed: 24395782
Nat Rev Clin Oncol. 2014 Apr;11(4):203-22
pubmed: 24569448
FEBS Open Bio. 2018 Aug 30;8(9):1544-1552
pubmed: 30186753
J Neuropathol Exp Neurol. 2004 May;63(5):474-83
pubmed: 15198126
Neuro Oncol. 2013 Oct;15(10):1429-37
pubmed: 23956241
Cancer Metastasis Rev. 2016 Jun;35(2):323-32
pubmed: 27023712
Front Oncol. 2018 Jul 03;8:208
pubmed: 30018881
JAMA Oncol. 2016 Jun 1;2(6):839
pubmed: 27100632
Lab Invest. 2003 Aug;83(8):1211-22
pubmed: 12920250
Ann Oncol. 2010 May;21(5):942-8
pubmed: 19840953
J Clin Oncol. 2016 Mar 20;34(9):945-52
pubmed: 26834058
Eur J Immunol. 2004 Nov;34(11):2955-63
pubmed: 15376193
N Engl J Med. 1990 Feb 22;322(8):494-500
pubmed: 2405271
Neurobiol Dis. 2010 Jan;37(1):13-25
pubmed: 19664713
Neurol Med Chir (Tokyo). 1991 Mar;31(3):152-5
pubmed: 1715049
Nat Rev Dis Primers. 2019 Jan 17;5(1):5
pubmed: 30655533
Breast. 2017 Oct;35:109-114
pubmed: 28709114
Cancer Treat Rev. 2004 Oct;30(6):515-20
pubmed: 15325032
J Thorac Dis. 2019 Jan;11(Suppl 1):S102-S112
pubmed: 30775033
Clin Cancer Res. 2016 Oct 15;22(20):5130-5140
pubmed: 27435396
Brain Res. 2008 Sep 10;1229:1-17
pubmed: 18644352
Oncol Rep. 2002 Jul-Aug;9(4):683-8
pubmed: 12066192
PLoS One. 2013 Aug 05;8(8):e69182
pubmed: 23940516
Cancer Res. 2001 Jul 1;61(13):5242-7
pubmed: 11431365
Methods Mol Biol. 2011;686:101-31
pubmed: 21082368
Curr Oncol. 2016 Jun;23(3):e239-47
pubmed: 27330360
Cancers (Basel). 2010 Dec 15;2(4):2100-37
pubmed: 24281220
J Natl Cancer Inst. 2013 Nov 6;105(21):1634-43
pubmed: 24108809
Oncology (Williston Park). 2018 Apr 15;32(4):156-63
pubmed: 29684234
Neurosurg Focus. 2014 Feb;36(2):E9
pubmed: 24484262
J Clin Oncol. 2009 Sep 10;27(26):4247-53
pubmed: 19667264
PLoS One. 2018 Jul 27;13(7):e0201425
pubmed: 30052658
Theranostics. 2018 Aug 7;8(16):4393-4408
pubmed: 30214628
Cancer Cell. 2014 Apr 14;25(4):501-15
pubmed: 24735924
Mol Med. 2016 Sep;22:32-40
pubmed: 26837070
Clin Cancer Res. 2012 Feb 15;18(4):938-44
pubmed: 22167408
Lancet Oncol. 2012 May;13(5):459-65
pubmed: 22456429
Front Oncol. 2017 Sep 25;7:230
pubmed: 28993799
JAMA Oncol. 2019 May 01;5(5):703-709
pubmed: 30844036
Acta Neuropathol. 2003 Jun;105(6):586-92
pubmed: 12734665
Ann Transl Med. 2018 Dec;6(Suppl 2):S110
pubmed: 30740431
Trends Cancer. 2018 Mar;4(3):176-196
pubmed: 29506669
J Clin Oncol. 2019 May 1;37(13):1081-1089
pubmed: 30860945
Acta Neurochir (Wien). 2014 Aug;156(8):1469-74
pubmed: 24809532
Surg Neurol Int. 2013 May 02;4(Suppl 4):S209-19
pubmed: 23717792
Expert Rev Neurother. 2016;16(2):223-32
pubmed: 26731270
J Cell Biol. 1998 Feb 23;140(4):947-59
pubmed: 9472045
Medicine (Baltimore). 2017 Feb;96(6):e6087
pubmed: 28178168
BMC Cancer. 2018 Apr 27;18(1):490
pubmed: 29703161
Fluids Barriers CNS. 2011 Jan 18;8(1):3
pubmed: 21349151
Radiat Oncol J. 2016 Mar;34(1):1-9
pubmed: 27104161
J Clin Oncol. 2015 Oct 20;33(30):3475-84
pubmed: 26282648
JAMA Oncol. 2017 May 01;3(5):666-671
pubmed: 27926948
J Clin Oncol. 2015 Jun 10;33(17):1881-8
pubmed: 25624436
Lung Cancer. 2018 Jul;121:12-17
pubmed: 29858020
Oncology (Williston Park). 2001 Sep;15(9):1144-54, 1157-8; discussion 1158, 1163-5
pubmed: 11589063
Lancet Oncol. 2013 Jan;14(1):64-71
pubmed: 23122784
Acta Neuropathol. 2005 Feb;109(2):181-90
pubmed: 15549331
Front Oncol. 2014 Sep 15;4:248
pubmed: 25309873
Breast Cancer Res. 2016 Jan 19;18(1):8
pubmed: 26781299
Neurosurgery. 2011 Jun;68(2 Suppl Operative):282-90; discussion 290
pubmed: 21336204
Clin Exp Metastasis. 2013 Aug;30(6):753-68
pubmed: 23456474
J Neurooncol. 2010 Mar;97(1):123-6
pubmed: 19727563
Semin Cell Dev Biol. 2015 Feb;38:2-6
pubmed: 25681530
Genet Res Int. 2011;2011:219189
pubmed: 22567347
Oncotarget. 2017 Jul 18;8(41):71223-71233
pubmed: 29050358
J Neurosurg. 2000 Apr;92(4):599-605
pubmed: 10761648
Nature. 2016 May 18;533(7604):493-498
pubmed: 27225120
Ann Transl Med. 2018 May;6(9):163
pubmed: 29911111
Eur J Cancer. 2014 Feb;50(3):611-21
pubmed: 24295639
Neurol Med Chir (Tokyo). 1994 Mar;34(3):183-6
pubmed: 7516049
Eur J Cancer. 2017 Oct;84:141-148
pubmed: 28810186
Anticancer Res. 2012 Nov;32(11):4655-62
pubmed: 23155227
CNS Neurol Disord Drug Targets. 2013 May 1;12(3):392-404
pubmed: 23469854
Cell. 2017 Mar 9;168(6):1101-1113.e13
pubmed: 28283064
Nat Commun. 2015 Apr 01;6:6716
pubmed: 25828099
Ann Neurol. 2011 Aug;70(2):194-206
pubmed: 21674586
Blood. 2010 Nov 4;116(18):3669-76
pubmed: 20631377
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):711-7
pubmed: 8040016
J Oncol Pract. 2016 Jun;12(6):536-42
pubmed: 27288470
Lancet Oncol. 2018 May;19(5):672-681
pubmed: 29602646
Anticancer Res. 2015 Nov;35(11):5797-806
pubmed: 26504000
N Engl J Med. 2018 Aug 23;379(8):722-730
pubmed: 30134131
Sci Rep. 2018 May 29;8(1):8267
pubmed: 29844613
Am Soc Clin Oncol Educ Book. 2018 May 23;38:65-77
pubmed: 30231328
Cancer Cell Int. 2015 Oct 24;15:102
pubmed: 26500454
Cancer. 2013 May 15;119(10):1768-75
pubmed: 23423860

Auteurs

Krutika Deshpande (K)

Department of Neurological Surgery, University of Southern California, Los Angeles, California 90033, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

Ian Buchanan (I)

Department of Neurological Surgery, University of Southern California, Los Angeles, California 90033, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

Vahan Martirosian (V)

Department of Neurological Surgery, University of Southern California, Los Angeles, California 90033, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

Josh Neman (J)

Department of Neurological Surgery, University of Southern California, Los Angeles, California 90033, USA.
Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90033, USA.
Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Thérapeutique › Radiothérapie › Irradiation crânienne › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Clinical Perspectives in Brain Metastasis.
questionsmedicales.fr › Techniques d'investigation › Techniques stéréotaxiques › Radiochirurgie › Clinical Perspectives in Brain Metastasis.